#biosimilar — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #biosimilar, aggregated by home.social.
-
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705 -
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705 -
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705 -
Celltrion Co. advanced its global expansion strategy at BIO USA 2025 in Boston, holding over 150 meetings to strengthen partnerships and pipeline, as it targets growth into a global big pharma.
#YonhapInfomax #Celltrion #BIOUSA #GlobalPartnerships #Biosimilar #AntibodyDrugConjugate #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=68476 -
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
#YonhapInfomax #SamsungBioepis #SamsungBiologics #SpinOff #CDMOBusiness #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64634 -
Happy #PharmPhriday! A question I get a lot is “what’s a #biosimilar?” Well, it’s like a #generic but for #biologics
Because a biologic is made from something living, you can’t exactly copy the drug recipe like you can with generics. There are also some differences in testing.
A biosimilar has no clinically meaningful differences from an existing FDA-approved biologic.
A generic drug demonstrates bioequivalence to an existing FDA-approved drug.
Infographic from https://www.fda.gov/media/166334/download